The Fcγ receptors CD64 (FcγRI) and CD32 (FcγRII) are frequently overexpressed on tumors, including AML cell lines and can impair the efficacy of therapeutic IgG1 antibodies via cis or trans interaction with their Fc portion27,28. The gene discussed is FCGR2A; the disease is acute myeloid leukemia.